Respiratory syncytial virus mRNA vaccine as well as preparation method and application thereof

By codon optimization of the nucleic acid sequence of the RSV virus F protein and using imidazolopyridyl lipid compounds, an mRNA vaccine that can express preF protein efficiently and last long in vivo was designed, solving the problem of insufficient protective efficacy of existing RSV vaccines, and achieving stronger and longer-lasting neutralizing antibody production and higher antiviral efficacy.

CN119818668APending Publication Date: 2025-04-15HEFEI AFANA BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411865110.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-18
Publication Date
2025-04-15

AI Technical Summary

Technical Problem

The existing RSV vaccines are not as durable as traditional recombinant protein vaccines in terms of protective efficacy, and it is difficult to express a stable preF conformation in the body for a long time, resulting in insufficient production of neutralizing antibodies.

Method used

By codon optimization of the nucleic acid sequence of the RSV virus F protein, an mRNA vaccine that can express preF protein efficiently and persistently in vivo was designed, and imidazolopyridyl lipid compounds were used as components of lipid nanoparticles to improve membrane fusion efficiency and antigen expression.

Benefits of technology

It achieves more efficient and long-lasting expression of preF protein in the body, inducing the body to produce stronger and longer-lasting neutralizing antibodies, thereby significantly enhancing the protective effect of RSV virus.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119818668A_ABST
    Figure CN119818668A_ABST
Patent Text Reader

Abstract

The invention discloses a respiratory syncytial virus mRNA (messenger Ribonucleic Acid) vaccine as well as a preparation method and application of the respiratory syncytial virus mRNA vaccine. A proper promoter, 5 '-UTR, 3'-UTR and 3 '-terminal PolyA are selected to be combined into a complete sequence for coding RSV virus preF, then mRNA is obtained through synthesis, reverse transcription and purification, and two sequences which express preF protein in a cell level and have high stability and strong binding capacity with a neutralizing antibody are obtained through screening from five nucleic acid sequences giving consideration to the expression level and the stability; according to the mRNA vaccine provided by the invention, the components of the lipid nanoparticles are improved, and the expression of a target antigen in vivo is enhanced, so that the prepared mRNA vaccine can generate a strong and lasting immune effect after immunizing a mouse and has stronger protective force on viruses.
Need to check novelty before this filing date? Find Prior Art